Francois Delhommeau

List of Publications by Year
in descending order

36 papers	7,868 citations	331670 21 h-index	361022 35 g-index
37 all docs	37 docs citations	37 times ranked	8071 citing authors

#	Article	IF	Citations
1	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434, 1144-1148.	27.8	3,221
2	Mutation in<i>TET2</i>in Myeloid Cancers. New England Journal of Medicine, 2009, 360, 2289-2301.	27.0	1,614
3	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 25-38.	16.8	792
4	New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 2011, 118, 1723-1735.	1.4	346
5	Two routes to leukemic transformation after a JAK2 mutationâ€“positive myeloproliferative neoplasm. Blood, 2010, 115, 2891-2900.	1.4	269
6	Clonal architecture of chronic myelomonocytic leukemias. Blood, 2013, 121, 2186-2198.	1.4	232
7	Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood, 2006, 108, 346-352.	1.4	221
8	The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood, 2007, 110, 1013-1021.	1.4	172
9	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood, 2011, 118, 2551-2555.	1.4	163
10	Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood, 2007, 109, 71-77.	1.4	154
11	The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood, 2008, 112, 2429-2438.	1.4	101
12	Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood, 2009, 114, 1628-1632.	1.4	96
13	Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nature Communications, 2016, 7, 12475.	12.8	95
14	Molecular aspects of myeloproliferative neoplasms. International Journal of Hematology, 2010, 91, 165-173.	1.6	63
15	Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia. Haematologica, 2017, 102, 1227-1237.	3.5	45
16	High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers. Blood Advances, 2020, 4, 3550-3557.	5.2	38
17	The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood, 2012, 119, 1190-1199.	1.4	34
18	TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. Stem Cells, 2014, 32, 2084-2097.	3.2	34

#	Article	IF	Citations
19	Role of TET2 Mutations in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2012, 7, 57-64.	2.3	32
20	Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera. Haematologica, 2011, 96, 775-778.	3.5	25
21	Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. International Journal of Molecular Sciences, 2018, 19, 3850.	4.1	24
22	The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica, 2011, 96, 590-601.	3.5	17
23	Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues. Journal of Theoretical Biology, 2018, 449, 103-123.	1.7	11
24	Systemic Dysfunction of Osteoblast Differentiation in Adipose-Derived Stem Cells from Patients with Multiple Myeloma. Cells, 2019, 8, 441.	4.1	11
25	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. Leukemia, 2022, 36, 126-137.	7.2	10
26	TP53 mutations: the dawn of Shwachman clones. Blood, 2018, 131, 376-377.	1.4	8
27	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes. Communications Biology, 2022, 5, 110.	4.4	8
28	Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells. Leukemia, 2021, , .	7.2	7
29	Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution. Leukemia Research, 2014, 38, 907-912.	0.8	6
30	Shwachmanâ€Diamond syndrome and solid tumors: Three new patients from the French Registry for Severe Chronic Neutropenia and literature review. Pediatric Blood and Cancer, 2021, 68, e29071.	1.5	4
31	Primary Plasma Cell Leukemia Mimicking an Adult T-Cell Leukemia-Lymphoma. Acta Cytologica, 2010, 54, 187-189.	1.3	3
32	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 276.	16.8	3
33	Reed Sternberg cell/lymphocyte rosettes in a bone marrow aspirate leading to the diagnosis of Hodgkin lymphoma. British Journal of Haematology, 2016, 175, 557-557.	2.5	1
34	Quantification of Toxoplasma gondii in Amniotic Fluid by Rapid Cycle Real-Time PCR. , 2002, , 133-138.		1
35	Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia. British Journal of Haematology, 2022, 198, 780-784.	2.5	1
36	Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated <i>NPM1</i>: a single center study. Leukemia and Lymphoma, 2022, , 1-9.	1.3	0